Oncogenic role and potential regulatory mechanism of fatty acid binding protein 5 based on a pan-cancer analysis

Abstract

As one member of fatty acid binding proteins (FABPs), FABP5 makes a contribution in the occurrence and development of several tumor types, but existing analysis about FABP5 and FABP5-related molecular mechanism remains limited. Meanwhile, some tumor patients showed limited response rates to current immunotherapy, and more potential targets need to be explored for the improvement of immunotherapy. In this study, we made a pan-cancer analysis of FABP5 based on the clinical data from The Cancer Genome Atlas database for the first time. FABP5 overexpression was observed in many tumor types, and was statistically associated with poor prognosis of several tumor types. Additionally, we further explored FABP5-related miRNAs and corresponding lncRNAs. Then, miR-577-FABP5 regulatory network in kidney renal clear cell carcinoma as well as CD27-AS1/GUSBP11/SNHG16/TTC28-AS1-miR-22-3p-FABP5 competing endogenous RNA regulatory network in liver hepatocellular carcinoma were constructed. Meanwhile, Western Blot and reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) analysis were used to verify miR-22-3p-FABP5 relationship in LIHC cell lines. Moreover, the potential relationships of FABP5 with immune infiltration and six immune checkpoints (CD274, CTLA4, HAVCR2, LAG3, PDCD1 and TIGIT) were discovered. Our work not only deepens the understanding of FABP5’s functions in multiple tumors and supplements existing FABP5-related mechanisms, but also provides more possibilities for immunotherapy.

Melanoma progression and prognostic models drawn from single-cell, spatial maps of benign and malignant tumors

“…Instead, as shown via Cox regression analysis (Fig. 5), it is the combined increased expression of FABP5 and CDK2 in melanocytes that points to a transcriptional state associated with poor clinical outcomes, which corroborate an increasing number of studies suggesting that FABP5 may be a suitable target for therapeutic intervention (40,45,46).…”

“…S13). Notably, spatial cluster #4 also included metabolic genes COX5B and FABP5, both of which have been implicated in modulating the pro-growth cancer metabolome (38)(39)(40). Mapping these spatially regulated genes onto the tumor confirmed their differential spatial expression (Fig.…”

Emerging Lipid Targets in Glioblastoma

“…In comparison with normal cells, the expressions of both FABP4 and FABP5 have been found to be higher in GBM cells. The expression of FABP4 has been associated with a poor prognosis, while its inhibition suppressed metastases in vivo and in vitro, highlighting FABP4 as a possible target for the treatment of GBM [79,80]. Gene expression analysis of surgical specimens found an elevated expression of FABP7 in GBM samples.…”

Mechanism of lncRNA SNHG16 on kidney clear cell carcinoma cells by targeting miR-506-3p/ETS1/RAS/ERK molecular axis

“…SNHG16 is located on human chromosome 17q25.1 and is first identified as an oncogene in neuroblastoma [ 13 ]. In recent years, the role of SNHG16 in KIRC has been gradually concerned; it has been confirmed that SNHG16 can participate in the development of KIRC through CDKN1A, STARD9, and other pathways, and is expected to a new direction in the diagnosis and treatment of KIRC [ 14 , 15 ]. Second, mitogen-activated protein kinase (MAPK) is one of the most important transduction pathways in cell signal transduction network [ 16 , 17 ].…”